그누보드5

본문 바로가기
사이트 내 전체검색
PIPELINE

PIPELINE.

BEY1107G

Glioblastoma treatment

An anti-cancer agent that selectively acts on CDK1 among the cyclin-dependent kinases (CDKs) that regulates the cell cycle

BEY1107G induces apoptosis through cell suicide mechanism by synchronizing the G2 / M cell cycle phases of the glioblastoma. In addition, BEY1107G inhibits the self renewal of cancer stem cells, demonstrating its effectiveness as a monotherapy.

When used in combination with Temozolomide a treatment for glioblastoma, it shows improved anti-cancer treatment effects. It is expected to overcome resistance and recurrence of cancer which is evident when Temozolomide is administered as a monotherapy.

Currently, BEY1107 is in phase I clnical trial and aims to enter into phase II clinical trial in the second half of 2019.

파이프 이미지

회원로그인

접속자집계

오늘
50
어제
131
최대
830
전체
114,429
그누보드5
Copyright © 소유하신 도메인. All rights reserved.